Indeed, it has been shown that anti-CD20 therapy (such as rituximab and ocrelizumab) effectively depletes CD20+T cells in both the PB and CSF of patients with MS [10, 25]. This evidence concerns the gene MS4A1 and myeloid sarcoma.